Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.

Slides:

Advertisements

Similar presentations

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Advertisements

وما أوتيتم من العلم إلا قليلاً. Prepared by: Abdo A Elfiky.

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells by Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman Blood.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

S. Sulaiman Shoab, MD, FCPS, FRCS, J. H. Scurr, MS, FRCS, P. D

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

by Matilde Murga, Oscar Fernandez-Capetillo, and Giovanna Tosato

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

VEGF therapy: risky business for established plaques?

EBV DNA: a Hodgkin lymphoma biomarker?

سرطان الثدي Breast Cancer

by James O. Armitage, and Dan L. Longo

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

An endothelial metronome breast cancer?

Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis by Lei Yao, Ombretta.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent by Sylvia T. Singer, Vivian.

by Sabah Sallah, and Jim Y. Wan

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Primary testicular lymphoma

by Ineke J. M. ten Berge, and René A. W. van Lier

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.

Latest lymphoma classification is skin deep

Concentrations of stromal cell-derived factor-1 and vascular endothelial growth factor in relation to the diameter of human follicles Akemi Nishigaki,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Malignancy-associated dermatomyositis: Retrospective case–control study from a single tertiary care center Laura Kooistra, BS, Claudia Ricotti, BS, Fabrizio.

by Yoshiyasu Aoki, Giovanna Tosato, Terry W

by Andrea J. O'Hara, Ling Wang, Bruce J. Dezube, William J

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

The measurements of RAGE, VEGF, and AGEs in the plasma and follicular fluid of reproductive women: the influence of aging Eriko Y. Fujii, M.D., Ph.D.,

Comparison of the bronchoalveolar lavage fluid (BALF) levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Comparison of the serum levels of the three vascular endothelial growth factor (VEGF) types in healthy volunteers and patients with idiopathic pulmonary.

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Treatment versus Transplant for Challenging Hematologic Disorders

Volume of GP infarcts. Volume of GP infarcts. The range of GP infarct volumes is 9–1021 μL. Laterality of the infarcts is apparent when infarcts are segregated.

sIgM levels or signaling and FISH lesions in CLL

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

Results of Initial Operations in Non–Small Cell Lung Cancer Patients With Single-Level N2 Disease Yasuhiko Ohta, MD, Yosuke Shimizu, MD, Hiroshi Minato,

Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter Joe B Putnam, MD, Garrett L Walsh, MD, Stephen G Swisher,

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

EN1 expression in breast cancer and clinical outcome.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Location of the ER mutations and frequencies per cohort.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

Percentage change from baseline in homeostatic model assessment (HOMA) score, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF),

Bar graph illustrating the rate of leak detection by CTM and MRM

Receiver operating characteristic curves show the diagnostic performance of the incremental CT protocol in the detection of lacunar infarction, without.

Validation of NAA's cancer specificity in lung cancer.

Empty basement membrane sleeves and endothelial sprouts.

Cancer-associated pathways and biomarkers of venous thrombosis

Balancing bleeding in brain metastases

Cold agglutinin disease

Presentation transcript:

Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi Iwamoto, and Robert Yarchoan Blood Volume 95(3):1109-1110 February 1, 2000 ©2000 by American Society of Hematology

VEGF levels in effusions from patients with malignant and nonmalignant disease.AIDS-PEL (n = 8), nonmalignant AIDS, no PEL (n = 4), ovarian cancer (n = 8), lung cancer (n = 5; open circles), breast cancer (n = 1; open square), thymic cancer (n = 2; closed c... VEGF levels in effusions from patients with malignant and nonmalignant disease.AIDS-PEL (n = 8), nonmalignant AIDS, no PEL (n = 4), ovarian cancer (n = 8), lung cancer (n = 5; open circles), breast cancer (n = 1; open square), thymic cancer (n = 2; closed circles) and nonmalignant samples (n = 5). Bars indicate the average of each group. Statistical significance versus AIDS-PEL was determined by Student t test analysis. Yoshiyasu Aoki et al. Blood 2000;95:1109-1110 ©2000 by American Society of Hematology